{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:22:39Z","timestamp":1783441359678,"version":"3.54.6"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vhri.2025.101570","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:00:33Z","timestamp":1768075233000},"page":"101570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Economic Evaluation and Budget Impact Analysis of Secukinumab as a Second-Line Treatment Among Patients With Psoriatic Arthritis Who Were Tumor Necrosis Factor Inadequate Responders in Thailand"],"prefix":"10.1016","volume":"54","author":[{"given":"Unchalee","family":"Permsuwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratree","family":"Sawangjit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyameth","family":"Dilokthornsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vhri.2025.101570_bib1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101570_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2025.101570_bib3","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.vhri.2025.101570_bib4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.vhri.2025.101570_bib5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s40744-021-00337-5","article-title":"Secukinumab efficacy on psoriatic arthritis GRAPPA-OMERACT core domains in patients with or without prior tumor necrosis factor inhibitor use: pooled analysis of four phase 3 studies","volume":"8","author":"Orbai","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.vhri.2025.101570_bib6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.vhri.2025.101570_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and Safety of subcutaneous secukinumab 150 mg with or without Loading Regimen in Psoriatic Arthritis: results from the FUTURE 4 Study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"issue":"9999","key":"10.1016\/j.vhri.2025.101570_bib8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vhri.2025.101570_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.vhri.2025.101570_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40273-015-0350-3","article-title":"The clinical and cost effectiveness of ustekinumab for the treatment of psoriatic arthritis: a critique of the evidence","volume":"34","author":"O\u2019Connor","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2025.101570_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.vhri.2022.10.005","article-title":"Cost-utility analysis of biologic disease-modifying antirheumatic drugs for patients with psoriatic arthritis in Thailand","volume":"34","author":"Dilokthornsakul","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2025.101570_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vhri.2019.03.002","article-title":"Cost-effectiveness of secukinumab versus other biologics in the treatment of psoriatic arthritis: an Argentinean perspective","volume":"20","author":"Aiello","year":"2019","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.vhri.2025.101570_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40258-019-00523-1","article-title":"Cost effectiveness of secukinumab versus other biologics and apremilast in the treatment of active psoriatic arthritis in Germany","volume":"18","author":"Gandjour","year":"2020","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.vhri.2025.101570_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13696998.2017.1384737","article-title":"Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective","volume":"21","author":"Goeree","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.vhri.2025.101570_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12962-018-0162-3","article-title":"Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective","volume":"16","author":"Purmonen","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"10.1016\/j.vhri.2025.101570_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s41669-020-00202-1","article-title":"Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab in the treatment of active psoriatic arthritis with concomitant moderate-to-severe psoriasis in the UK","volume":"4","author":"Schweikert","year":"2020","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"10.1016\/j.vhri.2025.101570_bib17","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/13696998.2023.2259609","article-title":"Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden","volume":"26","author":"Sigurdardottir","year":"2023","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.vhri.2025.101570_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 Study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.vhri.2025.101570_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-024-01122-2","article-title":"Safety of secukinumab from 1 million patient-years of exposure: experience from post-marketing setting and clinical trials","volume":"14","author":"Sun","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"10.1016\/j.vhri.2025.101570_bib20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2340\/00015555-2900","article-title":"Initial results of secukinumab drug survival in patients with psoriasis: a multicentre daily practice cohort study","volume":"98","author":"van den Reek","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.vhri.2025.101570_bib21","series-title":"Global Health Observatory Data: Life Tables by Country Thailand","year":"2020"},{"issue":"5","key":"10.1016\/j.vhri.2025.101570_bib22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/acr.24820","article-title":"All-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis: a systematic review and meta-analysis","volume":"75","author":"Chaudhary","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"56","key":"10.1016\/j.vhri.2025.101570_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21560","article-title":"Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation","volume":"21","author":"Corbett","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vhri.2025.101570_bib24","series-title":"Guidelines for Health Technology Assessment in Thailand","author":"Chaikledkaew","year":"2013"},{"key":"10.1016\/j.vhri.2025.101570_bib25","series-title":"Nonthaburi, Thailand: The Graphic System","article-title":"Guidelines for Health Technology Assessment in Thailand","author":"Chaikledkaew","year":"2009"},{"key":"10.1016\/j.vhri.2025.101570_bib26","series-title":"Reference Purchasing Price (Drug)","year":"2020"},{"key":"10.1016\/j.vhri.2025.101570_bib27","series-title":"Standard cost lists for health technology assessment","author":"Riewpaiboon","year":"2011"},{"key":"10.1016\/j.vhri.2025.101570_bib28","series-title":"Service Fee Announcement","year":"2018"},{"key":"10.1016\/j.vhri.2025.101570_bib29","series-title":"Consumer Price Index","year":"2024"},{"key":"10.1016\/j.vhri.2025.101570_bib30","series-title":"Currency Exchange Rate of Commercial Bank in Bangkok","year":"2025"},{"key":"10.1016\/j.vhri.2025.101570_bib31","series-title":"Department of provincial administration. Ministry of Interior. Population statistics from civil registration. Pathumthani T: The Office Statistics Registration Systems","year":"2024"},{"issue":"1","key":"10.1016\/j.vhri.2025.101570_bib32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.vhri.2025.101570_bib33","author":"Permsuwan","year":"2021"},{"issue":"11","key":"10.1016\/j.vhri.2025.101570_bib34","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101570_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.vhri.2025.101570_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.vhri.2025.101570_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7861\/clinmedicine.14-1-95","article-title":"Effectiveness of switching between biologics in psoriatic arthritis - results of a large regional survey","volume":"14","author":"Jani","year":"2014","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"10.1016\/j.vhri.2025.101570_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.vhri.2025.101570_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:37:21Z","timestamp":1783438641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925004960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S2212109925004960"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101570","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation and Budget Impact Analysis of Secukinumab as a Second-Line Treatment Among Patients With Psoriatic Arthritis Who Were Tumor Necrosis Factor Inadequate Responders in Thailand","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101570"}}